UOC
LVACU

UBS O'Connor’s LAVA Medtech Acquisition Corp. Unit LVACU Stock Holding History

UBS O'Connor’s Portfolio LVACU Stock Details LVACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-309,462
Closed -$3.24M – 915
2021
Q4 		$3.24M Buy
+309,462
New +$3.13M 0.03% 396

Other funds holding LVACU

CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

UBS O'Connor's LVACU Position: Q1 2022 in Review

UBS O'Connor sold out of LAVA Medtech Acquisition Corp. Unit (LVACU) in Q1 2022, closing a stake of 309,462 shares — an estimated $3.24M sold.

UBS O'Connor first reported a position in LVACU in Q4 2021 and held it in 1 quarter. The position peaked at $3.24M in Q4 2021. 17 funds tracked by Wall St. Rank hold LVACU as of Q1 2022.

  • UBS O'Connor reported no remaining LAVA Medtech Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • UBS O'Connor sold 309,462 LAVA Medtech Acquisition Corp. Unit shares in Q1 2022, an estimated $3.24M.
  • UBS O'Connor first reported a position in LAVA Medtech Acquisition Corp. Unit in Q4 2021 and held it in 1 quarter.
  • UBS O'Connor's LAVA Medtech Acquisition Corp. Unit position peaked at $3.24M in Q4 2021.
  • 17 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Unit as of Q1 2022.

Based on UBS O'Connor's 13F filing for Q1 2022, filed 16 May 2022.